1-4 of 4
Hinrich P. Hansen, PhD
Close
Sort by
Journal Articles

Tipifarnib Is Cytotoxic and a Drug Transporter Inhibiting Chemosensitizer in Hodgkin Lymphoma Tumor Cells.

Boris Boll, MD, Anna Lang, Peer Langendorf, Hinrich P. Hansen, PhD, Elke P. von Strandmann, PhD, Andreas Engert, Bastian von Tresckow, MD
Journal: Blood
Blood (2007) 110 (11): 1386.
https://doi.org/10.1182/blood.V110.11.1386.1386
Published: 2007
Journal Articles

Prenylation Inhibitors as Potential Therapeutic Drugs in Hodgkin Lymphoma.

Bastian von Tresckow, MD, Peer Langendorf, Elke Pogge von Strandmann, PhD, Stefanie Sasse, MD, Samir Tawadros, Andreas Engert, MD, Hinrich P. Hansen, PhD
Journal: Blood
Blood (2006) 108 (11): 2513.
https://doi.org/10.1182/blood.V108.11.2513.2513
Published: 2006
Journal Articles

Mistargeting of Normal Cells in Anti-CD30 Immunotherapy of Lymphoma Cells Is Blocked by Selective Metalloproteinase Inhibitor.

Vijaya L. Simhadri, Elke Pogge von Strandmann, PhD, Dennis A. Eichenhauer, Andreas Ludwig, PhD, Katrin S. Reiners, PhD, Andreas Engert, PhD, Hinrich P. Hansen, PhD
Journal: Blood
Blood (2006) 108 (11): 2518.
https://doi.org/10.1182/blood.V108.11.2518.2518
Published: 2006
Journal Articles

Tumor Cell-Derived HLA-B-Associated Transkript 3 (BAT3) Is a Ligand for NKp30 and Activates NK Cells.

Elke Pogge von Strandmann, PhD, Venkateswara R. Simhadri, Bastian von Tresckow, MD, Stefanie Sasse, MD, Katrin S. Reiners, PhD, Hinrich P. Hansen, PhD, Achim Rothe, MD, Peter Borchmann, MD, Peter J. McKinnon, PhD, Michael Hallek, Andreas Engert
Journal: Blood
Blood (2006) 108 (11): 643.
https://doi.org/10.1182/blood.V108.11.643.643
Published: 2006